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HIGHLIGHTS 32 
• Functional priorities in life of dystonia patients and their caregivers vary greatly 33 
• The effect of DBS on functional priorities did not correlate with motor outcome 34 
• Half of the motor ‘non-responder’ patients reported important changes in their 35 
priorities 36 
• The effect of DBS in dystonia should not be measured by motor outcome alone 37 
38 
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ABSTRACT  39 
Background: To systematically evaluate the effectiveness of deep brain stimulation of the 40 
globus pallidus internus (GPi-DBS) in dystonia on pre-operatively set functional priorities in 41 
daily living. 42 
Methods: Fifteen pediatric and adult dystonia patients (8 male; median age 32y, range 8-65) 43 
receiving GPi-DBS were recruited. All patients underwent a multidisciplinary evaluation 44 
before and 1-year post DBS implantation. The Canadian Occupational Performance Measure 45 
(COPM) first identified and then measured changes in functional priorities. The Burke-Fahn-46 
Marsden Dystonia Rating Scale (BFMDRS) was used to evaluate dystonia severity.  47 
Results: Priorities in daily functioning substantially varied between patients but showed 48 
significant improvements on performance and satisfaction after DBS. Clinically significant 49 
COPM-score improvements were present in 7/8 motor responders, but also in 4/7 motor non-50 
responders.  51 
Discussion: The use of a patient-oriented approach to measure GPi-DBS effectiveness in 52 
dystonia provides an unique insight in patients’ priorities and demonstrates that tangible 53 
improvements can be achieved irrespective of motor response.  54 
55 
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INTRODUCTION 56 
Dystonia is a movement disorder characterized by sustained or intermittent muscle 57 
contractions causing abnormal, often repetitive movements, abnormal posturing, or both. 58 
Dystonia comprises a heterogeneous patient population due to a broad spectrum of 59 
underlying acquired and inherited etiologies.[1]  60 
Over the past decades, deep brain stimulation of the globus pallidus internus (GPi-DBS) has 61 
emerged as a safe treatment option with a good response in non-lesional, mostly isolated 62 
forms of dystonia and a more variable response in combined forms of dystonia that are due to 63 
a static lesion or neurodegenerative process.[2] The application of this elective neurosurgical 64 
procedure therefore frequently gives rise to discussion, especially in secondary dystonia 65 
patients.  66 
The effect of GPi-DBS has been predominantly measured with objective standardized 67 
dystonia rating scales.2 However, the variability of dystonic symptoms within days, or even 68 
hours or minutes, makes it difficult to reliably capture overall dystonia severity in just one 69 
evaluation. Furthermore, it is unclear how dystonia severity reflects disease burden and there 70 
is only weak evidence that a reduction in symptoms in isolated forms of dystonia may 71 
correlate with meaningful improvements in functioning.[3,4]  72 
In line with the World Health Organization guidelines advocating patient-centered outcome 73 
measures,[5] we aimed to systematically evaluate the effect of DBS in terms of 74 
individualized functional priorities set by the patient and/or their caregivers.  75 
 76 
METHODS 77 
Patients 78 
We prospectively included fifteen consecutive dystonia patients that received GPi-DBS 79 
between January 2013 and July 2016. All patients were evaluated pre and 1-year post-80 
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operatively screened by a multidisciplinary team. The local ethical committee classified the 81 
study as care as usual. 82 
Outcome measures 83 
Priorities were identified by the Canadian Occupational Performance Measure (COPM). The 84 
COPM is an individualized outcome measure to capture everyday problems that impact daily 85 
functioning. Together with a trained occupational therapist, patients and/or caregivers 86 
imaginary walked through a typical day in the patient’s life to identify priorities that they 87 
would like to see improved by GPi-DBS. For the three most important priorities performance 88 
(1-10) and satisfaction (1-10) were rated. Change between pre- and postoperative ratings was 89 
used for further analyses. At the 1-year follow-up, patients and/or their caregivers were 90 
blinded for their pre-operative ratings. A difference of two or more points was considered 91 
clinically significant.[6] 92 
Dystonia severity was assessed with the motor subscale of the Burke-Fahn-Marsden dystonia 93 
rating scale (BFMDRS). Videos were blinded for operative status and rated by experienced 94 
clinicians (ALB, RB, KJP, MFC) who were blinded to treatment state. Mean total scores 95 
were calculated. In order to be able to compare the results in all patients (generalized and 96 
focal/segmental) the relative change in BFMDRS (% of improvement) was used for further 97 
analyses. In addition, patients were subdivided into motor ‘responders’ (>20% change in 98 
BFMDRS score) and ‘non-responders’ (<20% change in BFMDRS score).[7] For absolute 99 
scores, see supplementary table 1. 100 
 101 
Data-analysis 102 
Data-analysis was performed using Statistical Package for the Social Sciences (SPSS, version 103 
23.0). Due to the heterogeneity of the sample, medians and interquartile ranges (IQR) were 104 
used. Differences between pre- and postoperative scores were compared with the Wilcoxon 105 
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Signed Ranked Test for total group and the responders and non-responder subgroups. 106 
Correlations between the outcome measures were calculated with the Spearman’s ρ.  107 
 108 
RESULTS 109 
Baseline characteristics, etiology and pharmacological treatment of all 15 patients (8 male; 110 
median age 32y range 8-65; median disease duration 8y range 3-47) are shown in table 1.  111 
 112 
Individual priorities 113 
The 45 priorities (3 per patient) were categorized in self-care/activities of daily living (ADL) 114 
(n=10); comfort in sitting and sleep (n=9); communication (n=7); social/leisure activities 115 
(n=7); and mobility (n=12). Communication priorities involved the ability to use an electric 116 
communication device, sign language or normal social interaction without interference of 117 
dystonic posturing. Social activities included sports, interactive games or going out for 118 
dinner. Mobility comprised walking, cycling, driving a car or the use of public transport.  119 
For each patient, priorities comprised at least two categories. There was a very strong 120 
correlation between performance and satisfaction scores (ρ = 0.86, p<0.0001) and both scores 121 
significantly improved after the application of DBS (Table 2). At patient level, a clinically 122 
significant change in satisfaction in two or three individual priorities was reported in 73% 123 
(11) of the patients. In 47% all three priorities were improved, in 27% two priorities were 124 
improved, in 13% one priority was improved and in 13% none of the priorities was improved.  125 
 126 
Dystonia severity 127 
BFMDRS scores improved with a median change of 30% (pre 46.8 IQR 17.0-66.0 vs post 128 
35.4 IQR 11.3-53.0; p=0.027). Eight patients (53%) were classified as responders with a 129 
decrease in their BFMDRS of more than 20% and seven (47%) as non-responders. 130 
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The non-responders were two patients with cerebral palsy (case 8 and 14), one patient with a 131 
mitochondrial disorder (case 1), one patient with DYT-THAP1 (case 6) and three patients 132 
with segmental dystonia (case 3, 12 and 15). 133 
 134 
Priorities versus dystonia severity 135 
Change in dystonia severity did neither correlate with change in performance (ρ = -0.15, 136 
p=0.601) nor satisfaction score (ρ = 0.17, p=0.557).  137 
Seven of the eight responders reported a clinically significant improvement in performance 138 
and satisfaction on at least two or three individual functional priorities. In the group of non-139 
responders, despite the lower motor response, clinical significant improvement in at least two 140 
priorities was achieved in four of these patients for performance and three for satisfaction, 141 
with a statistically significant change in COPM score (Case 6, 12, 14 and 15, p=0.017).  142 
 143 
DISCUSSION 144 
This prospective case series aimed to systematically evaluate the effectiveness of GPi-DBS 145 
as measured with change in preoperatively set functional priorities. The priorities of the 146 
patients and their caregivers lay within the domains of ADL, seating and sleep, 147 
communication, social/leisure activities and mobility. A clinically significant motor response 148 
coincided with improvements in functional priorities in 7/8 patients. Interestingly, half of the 149 
motor ‘non-responder’ patients also showed a clinically significant change in two or three 150 
priorities. Our findings are in line with a previous study in childhood dystonia showing that 151 
DBS may lead to improvement of functional goals also in patients with only moderate to 152 
‘insignificant’ motor response.[8] 153 
In contrast to the vast majority of efficacy studies primarily focusing on motor response, we 154 
evaluated effect of GPi-DBS by looking at functional priorities. These priorities provide an 155 
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unique insight in what patients and their caregivers identify as most important aspects in 156 
daily living. Given the heterogeneous nature of dystonia, it is not surprising that needs varied 157 
greatly between patients. An additional advantage is that this method may facilitate 158 
recognition of patients that might be unsuitable for the procedure due to goals that are 159 
unrealistic or not likely to be achieved by GPi-DBS. One might argue that with a goal-160 
oriented approach changes are subjective to the patients’ perception of improvement rather 161 
than objective symptom reduction. In addition, a potential placebo effect cannot be excluded 162 
in the absence of a control group. However, we agree with Kubu and colleagues that the main 163 
goal of DBS is to improve quality of life as perceived by the patient more than by the 164 
clinician, and that the effect of an elective neurosurgical option as DBS should be measured 165 
accordingly.[9] In the future, it would be useful to objectify the patient centered outcome. 166 
This can be done by transforming the patients’ priorities into a treatment goal and pre-167 
operatively decide with the patient and caregivers when the goal is met, for instance by using 168 
the goal attainment scale.  169 
The heterogeneous patient sample may be seen as a limitation, both in terms of age as well as 170 
etiology. On the other hand, it can be seen as an advantage for the generalizability of the 171 
study. We did not correct for changes in medication, which could account for some of the 172 
perceived improvements. We realize that our conclusions are bases on a small case series 173 
with a possibly limited power, but hope these results serve as a pilot study to trigger future 174 
studies focusing on the effectiveness of GPi-DBS in dystonia. First to assess to what extent a 175 
good motor outcome corresponds with the perceived outcome on the patient’s priorities. This 176 
may not always be the case, as 1/8 motor responders did not reach a significant improvement 177 
on his priorities, and might provide clarity in the repeatedly reported discrepancy between 178 
motor outcome and patient reported outcome. A systematical use of patient centered 179 
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outcomes might shine a new light on the current opinion that GPi-DBS is more effective in 180 
isolated than in combined forms of dystonia.   181 
In conclusion, the effect of GPi-DBS should be measured not by motor symptom reduction 182 
alone, as clinically significant improvements on individual predefined priorities can be 183 
achieved irrespective of motor response. In addition, a goal- or patient-oriented approach 184 
provides unique insights in the priorities in daily living of dystonia patients and their 185 
caregivers. This may not only be of added value for DBS candidates, but also for patients 186 
across the entire dystonia population. 187 
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Table 1: Patient characteristics and pharmacological treatment 233 
Pt Gender
/ age 
(yr) 
Body 
distribution 
Isolated or 
combined 
Etiology Pre-operative medical 
treatment 
Post-operative medical 
treatment 
1 M/8 Generalized Combined 
(spasticity) 
Mitochondr
ial disorder 
Gabapentin 100mg; 
intrathecal baclofen 3ug/hr 
Unchanged 
2 M/8 Generalized Isolated Idiopathic THP 20mg No 
3 M/18 Segmental Isolated Idiopathic THP 24mg; BTX THP 24mg 
4 F/22 Generalized Isolated ACTB 
mutation 
THP 16mg; tramadol 50mg THP 12mg; clonazepam 
1.5mg; clozapine 18.75; 
BTX 
5 F/32 Segmental Isolated Idiopathic Ibuprofen; BTX No 
6 M/9 Generalized Isolated DYT-
THAP1 
THP 21mg; baclofen 12.5mg THP 11mg 
7 M/22 Segmental Isolated TTPA Vitamin E Unchanged 
8 M/47 Generalized Combined 
(spasticity) 
Cerebral 
palsy 
Antidepressants Unchanged 
9 M/53 Segmental Isolated Idiopathic Clonazepam 0.5mg; BTX BTX 
10 F/65 Segmental Combined 
(parkinsonism) 
Idiopathic Pramipexole; L-dopa; 
Diazepam 5mg; BTX  
Pramipexole; L-Dopa 
11 F/48 Generalized Isolated ACTB 
mutation  
THP 12mg; clozapine 
12.5mg; oxazepam 10mg; 
diclofenac; BTX 
antidepressant 
THP 12mg; clozapine 
12.5mg; antidepressant 
12 F/63 Segmental Isolated Idiopathic Clonazepam 2.5mg Clonazepam 0.5mg 
13 M/62 Segmental Isolated Idiopathic BTX Clonazepam 1.0mg; BTX 
14 F/8 Generalized Combined 
(spasticity) 
Cerebral 
palsy 
THP 1.5mg; baclofen 12mg; 
gabapentin 600mg; 
clonazepam 0.5mg 
Unchanged 
15 F/63 Segmental Isolated Idiopathic No No 
 234 
ACTB: beta-actin gene; BTX: botulinum toxin injections; THP: trihexiphenidyl; TTPA α-235 
tocopherol transfer protein – vitamin E.  236 
237 
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Table 2: Pre- and postoperative COPM scores for all functional priorities and per 238 
subcategory 239 
 COPM-Performance COPM-Satisfaction 
 Baseline 1 year Improved 
priorities† 
Baseline 1 year Improved 
priorities† 
All priorities 3.0 (1.0-4.0) 7.0 (5.0-8.0) 32/45* 2.0 (1.0-3.5) 7.0 (4.0-8.5) 31/45* 
- 
itting and sleep 
3.0 (2.0-4.0) 7.0 (5.5-8.0) 8/9 2.0 (1.5-3.5) 7.0 (3.5-9.0) 5/9 
- 
elf-care/ADL 
1.5 (1.0-4.3) 6.0 (2.5-7.3) 6/10 1.5 (1.0-3.0) 6.5 (2.5-7.3) 7/10 
- 
ommunication 
4.0 (3.0-4.0) 8.0 (6.0-10.0) 5/7 3.0 (1.0-4.0) 9.0 (7.0-9.0) 6/7 
- 
ocial/leisure 
3.0 (1.0-4.0) 7.0 (3.0-7.0) 4/7 3.0 (1.0-4.0) 6.0 (1.0-7.0) 4/7 
- 
ransfer 
2.5 (1.3-4.8) 6.5 (5.3-7.0) 9/12 2.0 (1.0-3.8) 6.5 (5.3-8.8) 9/12 
 240 
ADL activities of daily living; †Change or 2 point or more between baseline and 1-year post-241 
operative score *p<0.0001 242 
 243 
 244 
 245 
 246 
